PL1904056T3 - Zastosowanie makrolidu do przywracania czucia rogówkowego - Google Patents

Zastosowanie makrolidu do przywracania czucia rogówkowego

Info

Publication number
PL1904056T3
PL1904056T3 PL06787603T PL06787603T PL1904056T3 PL 1904056 T3 PL1904056 T3 PL 1904056T3 PL 06787603 T PL06787603 T PL 06787603T PL 06787603 T PL06787603 T PL 06787603T PL 1904056 T3 PL1904056 T3 PL 1904056T3
Authority
PL
Poland
Prior art keywords
macrolide
corneal sensation
restore corneal
restore
sensation
Prior art date
Application number
PL06787603T
Other languages
English (en)
Inventor
Gholam A Peyman
Original Assignee
Minu Llc
Optivue L L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/183,355 external-priority patent/US20070014760A1/en
Application filed by Minu Llc, Optivue L L P filed Critical Minu Llc
Publication of PL1904056T3 publication Critical patent/PL1904056T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL06787603T 2005-07-18 2006-07-18 Zastosowanie makrolidu do przywracania czucia rogówkowego PL1904056T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/183,355 US20070014760A1 (en) 2005-07-18 2005-07-18 Enhanced recovery following ocular surgery
US11/263,737 US20070015697A1 (en) 2005-07-18 2005-11-01 Enhanced ocular neuroprotection and neurostimulation
PCT/US2006/027713 WO2007011880A2 (en) 2005-07-18 2006-07-18 Enhanced ocular neuroprotection/neurostimulation
EP06787603A EP1904056B1 (en) 2005-07-18 2006-07-18 Use of a macrolide to restore corneal sensation

Publications (1)

Publication Number Publication Date
PL1904056T3 true PL1904056T3 (pl) 2009-09-30

Family

ID=37669471

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06787603T PL1904056T3 (pl) 2005-07-18 2006-07-18 Zastosowanie makrolidu do przywracania czucia rogówkowego

Country Status (6)

Country Link
US (3) US7833966B2 (pl)
EP (1) EP1904056B1 (pl)
AU (1) AU2006270041B2 (pl)
CA (1) CA2615990A1 (pl)
PL (1) PL1904056T3 (pl)
WO (1) WO2007011880A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234385A1 (en) * 2002-05-09 2003-11-11 Michael S. Brogan Electrical stimulation unit and waterbath system
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20100233194A1 (en) * 2007-03-30 2010-09-16 Jean-Philippe Combal Treatment of neovascular ocular disease states
WO2008137617A1 (en) * 2007-05-04 2008-11-13 Allergan, Inc. Use of cyclosporines in the treatment of patients with intraocular lenses
ES2667945T3 (es) * 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
WO2009114010A1 (en) * 2008-03-11 2009-09-17 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US7678078B1 (en) * 2008-10-21 2010-03-16 KMG Pharma LLC Intravitreal injection device, system and method
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
EP2482818A4 (en) * 2009-09-29 2014-04-09 Eyegate Pharmaceuticals Inc POSITIVELY CHARGED POLY (D, L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND METHODS OF MAKING SAME
ES2649890T3 (es) * 2009-10-23 2018-01-16 Nexisvision, Inc. Enervación corneal para el tratamiento de dolor ocular
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20120156202A1 (en) * 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
FR2997079B1 (fr) * 2012-10-24 2015-01-23 Michelin & Cie Polyamine polyaromatique soufree utilisable pour la synthese de polyuree
EP3145549A4 (en) * 2014-05-23 2018-02-14 Ocular Technologies Sàrl Topical formulations and uses thereof
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
ITUB20169937A1 (it) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
AU2017227585C1 (en) 2016-02-29 2022-05-26 Sun Pharmaceutical Industries Limited Topical cyclosporine-containing formulations and uses thereof
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
WO2021186041A1 (en) * 2020-03-19 2021-09-23 Universität Rostock Josamycin for use in prevention and treatment of fibrosis
CN117462653B (zh) * 2023-11-28 2024-08-30 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 抑瘤素m在制备促进角膜上皮损伤修复的药物中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
DE3851152T2 (de) 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
DE69016515T2 (de) 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Wässriges flüssiges Mittel zur äusserlichen Anwendung.
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
JPH0710752A (ja) 1993-06-23 1995-01-13 Tokushu Meneki Kenkyusho:Kk アレルギー性及び自己免疫疾患治療用新規医薬組成物
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US6179817B1 (en) 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
JPH0930966A (ja) 1995-07-24 1997-02-04 Gakuzo Tamura 眼科用新規製剤
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
JP2000507997A (ja) 1996-02-09 2000-06-27 サーフェス ソルーションズ ラボラトリーズ インコーポレイテッド 水性の親水性被覆組成物及びそれから製造した物品
AU2250097A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
US5952371A (en) 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
JPH10218787A (ja) 1997-02-06 1998-08-18 Akio Okamoto 神経栄養因子による眼科用組成物
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20030181692A1 (en) 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
ZA989885B (en) 1997-10-31 1999-05-05 Abbott Lab Use of macrolides for the treatment of cancer and macular degeneration
CZ287497B6 (cs) 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
DK1056454T3 (da) 1998-02-23 2003-08-18 Fujisawa Pharmaceutical Co Anvendelse af makrolidforbindelser til behandling af glaukom
DE19810655A1 (de) 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
JP2002509555A (ja) 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
KR100406823B1 (ko) 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
CZ20013769A3 (cs) 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
CN1378445B (zh) * 1999-08-06 2013-02-06 得克萨斯系统大学评议会 药物释放生物可降解纤维植入物
JP2001064198A (ja) 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
DK1142566T3 (da) * 2000-04-07 2004-02-09 Medidom Lab Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
CN1127955C (zh) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
CN1204919C (zh) 2000-08-30 2005-06-08 中国科学院化学研究所 长效环孢素眼内释药体系
AU2001292881A1 (en) 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US6440942B1 (en) * 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
US6462026B1 (en) * 2001-02-16 2002-10-08 Enanta Pharmaceuticals, Inc. Bicyclic leucomycins
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6436906B1 (en) * 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
ES2256450T3 (es) 2001-04-20 2006-07-16 Debiopharm S.A. Ciclosporina modificada utilizable como profarmaco y su uso.
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
WO2003047525A2 (en) * 2001-12-03 2003-06-12 The Regents Of The University Of California Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
AU2002231703B2 (en) 2001-12-14 2007-03-29 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
CN1456350A (zh) 2002-05-10 2003-11-19 刘继东 环孢素眼用凝胶
US20040162315A1 (en) * 2002-07-23 2004-08-19 Hellberg Mark R. Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
AU2003256068A1 (en) 2002-08-09 2004-02-25 Sucampo Pharmaceuticals, Inc. Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents

Also Published As

Publication number Publication date
WO2007011880A2 (en) 2007-01-25
US7833966B2 (en) 2010-11-16
AU2006270041B2 (en) 2011-08-18
CA2615990A1 (en) 2007-01-25
WO2007011880A3 (en) 2007-06-21
EP1904056A2 (en) 2008-04-02
AU2006270041A1 (en) 2007-01-25
EP1904056B1 (en) 2009-04-29
US20080108579A1 (en) 2008-05-08
US20110039790A1 (en) 2011-02-17
US20070078077A1 (en) 2007-04-05
US8202840B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
PL1904056T3 (pl) Zastosowanie makrolidu do przywracania czucia rogówkowego
GB0505942D0 (en) Human to mobile interfaces
IL185767A0 (en) Use of an artificial sweetener to enhance absorption of nicotine
EP2044585A4 (en) SIMULATOR OF HUMAN MOVEMENT
IL188240A0 (en) Crystalline modifications to pyraclostrobin
EP1755496A4 (en) SPACER FOR TISSUE
GB0427444D0 (en) Improvements relating to skin dressings
GB0509845D0 (en) Preparation of therapeutic foam
GB0700235D0 (en) Improvements relating to medical devices
IL193597A0 (en) Conjunctival tissue system
GB2458228B (en) External preparation for skin
PL2049127T3 (pl) N-metanokarbapochodne do leczenia chorób serca
IL197433A0 (en) Fillings
GB0813924D0 (en) Skin cleaner
EP2039340A4 (en) COMPOSITION FOR CLEANING THE SKIN
GB0908728D0 (en) Skin cleansing compositions
GB0410586D0 (en) Improvements relating to patient turning devices
GB0603167D0 (en) Skin application
IL172276A0 (en) Cross-reference to related application
EP2042153A4 (en) skin cosmetic
GB0606921D0 (en) Skin dressing
GB0428268D0 (en) Pulsing wristband to induce sleep
TWM301010U (en) Improved structure of spring bed
GB0523304D0 (en) Improvements relating to medical devices
GB0525109D0 (en) Improvements relating to medical devices